← Back to headlines
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.
24 Feb, 20:38 — 24 Feb, 20:38
ℹOnly 1 source covers this story
